ライフサイエンスコーパス: clinical outcome

1 xpert advice from cardiologists will improve clinical outcome.

2 cy, leading to treatment resistance and poor clinical outcome.

3 associated with improved cerebral edema and clinical outcome.

4 at there are molecular subtypes differing in clinical outcome.

5 microbial agents prescribed, if any, and the clinical outcome.

6 suppression of immunity is often related to clinical outcome.

7 ioblastoma-like molecular features with poor clinical outcome.

8 d implications for tumour aggressiveness and clinical outcome.

9 cells (MCs) in the CNS, leading to improved clinical outcome.

10 udy is needed to assess safety and long-term clinical outcome.

11 565887) associated with serum creatinine and clinical outcome.

12 n cancers and its levels correlate with poor clinical outcome.

13 earlier AVR in these patients might improve clinical outcome.

14 plantation for evaluation of donor lungs and clinical outcome.

15 nti-inflammatory response that portends poor clinical outcome.

16 ibutions of each subtype of CRCs to distinct clinical outcome.

17 (HGSC) is an aggressive cancer with a worse clinical outcome.

18 and predicts the rate of aneurysm growth and clinical outcome.

19 opy number and expression were predictive of clinical outcome.

20 otherapy; which we postulate would relate to clinical outcome.

21 neous T-cell lymphoma (CTCL) portend a worse clinical outcome.

22 Adjunctive use can enhance clinical outcomes.

23 histological subtypes and the prediction of clinical outcomes.

24 lication in cirrhosis that adversely affects clinical outcomes.

25 potassium removal can be modified to improve clinical outcomes.

26 vation myocardial infarction did not improve clinical outcomes.

27 past two decades has substantially improved clinical outcomes.

28 linositol 3-kinase (PI3K) signaling and poor clinical outcomes.

29 n addition, MSI2 levels were associated with clinical outcomes.

30 e if our preliminary findings translate into clinical outcomes.

31 riprocedural factors translating into poorer clinical outcomes.

32 the effects of various fibrinolytic drugs on clinical outcomes.

33 acute ICH is safe and effective in improving clinical outcomes.

34 cits marked differences in SIV infection and clinical outcomes.

35 in postprocedural hemodynamics and long-term clinical outcomes.

36 hospital process of care measures and 1-year clinical outcomes.

37 , which, in turn, impacted associations with clinical outcomes.

38 ated psychosis (DUP) is associated with poor clinical outcomes.

39 th daptomycin for VRE-BSI and with evaluable clinical outcomes.

40 ictor) and the relation between VR and other clinical outcomes.

41 er the patients' first CT study to determine clinical outcomes.

42 with similar 30-day, 12-month, and 24-month clinical outcomes.

43 , cytolytic induction substantially improved clinical outcomes.

44 y bite, but different species cause distinct clinical outcomes.

45 sed strategy to limit resistance and improve clinical outcomes.

46 he non-SMGs that were highly associated with clinical outcomes.

47 cell levels in the airways and a spectrum of clinical outcomes.

48 a number of cancer types, resulting in poor clinical outcomes.

49 etastatic prostate cancer for correlation to clinical outcomes.

50 abolism contributes to many of these adverse clinical outcomes.

51 TR, which may potentially result in improved clinical outcomes.

52 he effectiveness of therapeutics and improve clinical outcomes.

53 on cancers spanning diverse tumor stages and clinical outcomes.

54 has been consistently associated with worse clinical outcomes.

55 of ibrutinib therapy contributes to altered clinical outcomes.

56 on holding the greatest potential to improve clinical outcomes.

57 n) consistent with observed population-level clinical outcomes.

58 f the hypothesized mediator of activation on clinical outcomes.

59 nts, particularly at institutions with worse clinical outcomes.

60 ic episodes but does not affect longitudinal clinical outcomes.

61 s and help correlate pathogenic markers with clinical outcomes.

62 rameters and to study their association with clinical outcomes.

63 , and its expression is correlated with poor clinical outcomes.

64 tically ill patients is associated with poor clinical outcomes.

65 s found against the non-laboratory-confirmed clinical outcomes.

66 d may influence affect, management style and clinical outcomes.

67 nflammation, and correlate measurements with clinical outcomes.

68 hether expression levels are associated with clinical outcomes.

69 al links between DUP, striatal circuitry and clinical outcomes.

70 search is needed on procedural and long-term clinical outcomes.

71 imen, including use of a fluoroquinolone, on clinical outcomes.

72 se and blood-brain barrier integrity dictate clinical outcomes.

73 therapy for CNVM was associated with better clinical outcomes.

74 oversizing was documented on procedural and clinical outcomes.

75 results) and were generally ineffective for clinical outcomes (18 reviews with 6 mixed and 9 general

76 ng both process of care (3 of 4 reviews) and clinical outcomes (3 reviews equally distributed between

77 iews and 12 of 13 reviews, respectively) and clinical outcomes (7 of 12 reviews and 3 of 5 reviews, r

78 Surrogate biomarkers for clinical outcomes afford scientific and economic efficie

79 epsis induction, with ELA providing the best clinical outcome after 24 hours.

80 patial clues for promoting regeneration, the clinical outcome after nerve damage is frequently poor.

81 n in our understanding of the prevalence and clinical outcomes after adrenalectomy in APA patients ha

82 usly assessed in single-center cohorts, with clinical outcomes after allogeneic HCT within this prosp

83 of 10 previously identified biomarkers with clinical outcomes after allogeneic HCT.

84 Therefore, genetic mutations may predict clinical outcomes after allogeneic hematopoietic stem-ce

85 Clinical outcomes after surgical treatment of mitral reg

86 er, randomized clinical trial is to evaluate clinical outcomes after treatment of localized gingival

87 hthalmic suspension versus vehicle, based on clinical outcomes, after cataract surgery in patients wi

88 training on measures of functional status or clinical outcomes (all p > 0.10).

89 airs associated with biological phenotype or clinical outcome, allowing for building predictive model

90 aking use of e-POCT's advantages in terms of clinical outcome and antibiotic prescription.

91 TLESS S-ICD (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) re

92 f chronic infection-is a strong predictor of clinical outcome and is highly variable across infected

93 turnaround time, which leads to compromised clinical outcome and promotes the spread of antibiotic r

94 rs that are intended to be substitutes for a clinical outcome and to accurately predict benefit or ha

95 gate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of d

96 A retrospective cohort study assessing clinical outcomes and a prospective cohort study assessi

97 epartment mechanical ventilation protocol on clinical outcomes and adherence to lung-protective venti

98 assess longer-term effectiveness, as well as clinical outcomes and adverse effects.

99 re, resulting in substantial improvements in clinical outcomes and cost savings.

100 AS programs results in major improvements in clinical outcomes and cost, making ERAS an important exa

101 ith stable coronary artery disease to assess clinical outcomes and cost-effectiveness.

102 rging viral factors that are associated with clinical outcomes and discuss their utility in a clinica

103 Clinical outcomes and health care use through 6 months w

104 he dynamic wound microbiome is indicative of clinical outcomes and may be a valuable guide for person

105 e time of transplantation, predicts relevant clinical outcomes and may perform better to predict pati

106 ating lymphocytes (TILs) are associated with clinical outcomes and may predict the efficacy of chemot

107 to treat unresectable NSCLC afford promising clinical outcomes and rates of toxic effects compared wi

108 diotherapy delivery is associated with worse clinical outcomes and survival.

109 involved in ovarian cancer progression, poor clinical outcome, and chemotherapy resistance.

110 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of th

111 iming relative to transplant, posttransplant clinical outcomes, and cost.

112 acy as well as energy intakes, gut function, clinical outcomes, and how well nutritional variables pr

113 otic administration between 24 and 72 hours, clinical outcomes, and readmissions for EOS.

114 g population characteristics, interventions, clinical outcomes, and source of funding.

115 e not been designed to detect differences in clinical outcomes, and thus no significant differences b

116 zed multicenter trial provides evidence that clinical outcomes are comparable in DP with or without i

117 However, results on long-term clinical outcomes are lacking.

118 plore differences in severity of disease and clinical outcomes are lacking.

119 , diagnosis, and management are lacking; and clinical outcomes are poorly established.

120 Clinical outcomes are similar up to 1 year.

121 Such clinical outcomes are typically observed in immunosuppre

122 f viral genetic differences to phenotypic or clinical outcomes, are highlighted as well.

123 rt phase 3 studies to assess longer-term and clinical outcomes, as well as safety.

124 METHODS AND We analyzed data from the Clinical Outcomes Assessment Program, a registry of all

125 ologists, neuropsychologists, and experts in clinical outcomes assessments, working in collaboration

126 These findings provide evidence for improved clinical outcomes associated with insulin pump therapy c

127 athology of TBI in mice, including important clinical outcomes associated with mortality in this inju

128 SK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, hig

129 c results, treatment decisions, and ultimate clinical outcomes, assuming use of the standard Xpert ve

130 tically examines the epidemiological data on clinical outcomes attributed to AF and summarizes curren

131 We aimed to compare clinical outcomes between ICD patients followed-up in a

132 We found no differences in clinical outcomes between MGUS patients and KT controls.

133 baseline ICH volume, haematoma expansion and clinical outcomes between NOAC-ICH versus vitamin K anta

134 To date, differences in the clinical outcomes between the 2 cohorts have not been ex

135 METHODS AND Randomized trials reporting clinical outcomes beyond 1 year and comparing BVS with e

136 dergoing PCI, DES was associated with better clinical outcomes beyond 2 years of follow-up.

137 on targeting anxiety and depression improves clinical outcome compared with referral to outpatient co

138 ddition of buparlisib to paclitaxel improves clinical outcomes compared with paclitaxel and placebo i

139 ructured to ensure that short- and long-term clinical outcomes continue to improve.

140 entation interventions, especially regarding clinical outcomes, cost effectiveness and contextual iss

141 al simulation, we project the 5- and 20-year clinical outcomes, costs, and incremental cost-effective

142 MDSC burden correlates with poorer clinical outcomes, credited to their ability to suppress

143 pharmacokinetic/pharmacodynamic values, and clinical outcome data.

144 tient number >15, report of precision and/or clinical outcomes data, and at least 6 months of follow-

145 Secondary clinical outcomes demonstrated no significant difference

146 opulation with different causes of death and clinical outcomes during hospitalization, and the effect

147 npatient penicillin allergy testing affected clinical outcomes during hospitalization.

148 Clinical outcomes evaluated included pain, joint swellin

149 Clinical outcomes evaluated were fractures and adverse e

150 logy, a pathway thought to contribute to the clinical outcomes following intrauterine HCMV infection.

151 chemical profiles are a major determinant of clinical outcome for a given treatment.

152 n breast cancer patients and predicts a poor clinical outcome for breast cancer patients.

153 signs and symptoms, laboratory results, and clinical outcome for foodborne and wound botulism patien

154 he infecting S. epidermidis isolate with the clinical outcome for the infected patient.

155 sory cortex somatotopy can predict long-term clinical outcomes for carpal tunnel syndrome.

156 designated "RP-G28," significantly improved clinical outcomes for lactose digestion and tolerance.

157 t of molecular targeted therapies to improve clinical outcomes for the specific subtypes of breast ca

158 and 61.4 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not dif

159 Whilst their ability to predict clinical outcomes has been extensively reviewed, there h

160 ether correcting metabolic acidosis improves clinical outcomes has not been conducted, results from s

161 ut-free areas, but the impact of policies on clinical outcomes has not been evaluated.

162 The impact of POCD on clinical outcomes has yet to be studied.

163 These clinical outcomes have been associated with characterist

164 of AURKA overexpression associated with poor clinical outcomes have been attributed to increased cell

165 axel dose, and coating morphologies, varying clinical outcomes have been observed with different DCBs

166 ena(INV) expression both correlate with poor clinical outcome in breast cancer patients.

167 GARD independently predicted clinical outcome in breast cancer, lung cancer, glioblas

168 s are associated with cancer progression and clinical outcome in cancer patients.

169 cleaved LC3 expression correlates with poor clinical outcome in ESCC.

170 verexpression of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast canc

171 arks a CAF population that adversely impacts clinical outcome in human lung cancer.

172 rogrammes, was also associated with inferior clinical outcome in human PCs.

173 gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor surviva

174 sociated with lymph node metastasis and poor clinical outcome in OSCC.

175 tial of post-PCI FFR measurements to predict clinical outcome in patients from FAME 1 and 2 trials (F

176 acute MRI lesion patterns for discriminating clinical outcome in traumatic brain injury.

177 Five service organisation features predicted clinical outcomes in 2014-15.

178 hyperglycosylation, which is associated with clinical outcomes in acute HF.

179 Myocardial fibrosis is linked with adverse clinical outcomes in adults after tetralogy of Fallot re

180 TATION: KGF did not improve physiological or clinical outcomes in ARDS and might be harmful to patien

181 Dabrafenib plus trametinib improves clinical outcomes in BRAF(V600)-mutant metastatic melano

182 I (AKI-UO) and examined its association with clinical outcomes in CLD patients.

183 he use of the radial artery (RA) can improve clinical outcomes in coronary artery bypass graft surger

184 systematically assess their association with clinical outcomes in different subgroups in the ICU.

185 serve as biomarkers associated with adverse clinical outcomes in HFpEF.

186 of translational studies that better predict clinical outcomes in humans, improve the success of clin

187 elevated expression of GADD45B confers poor clinical outcomes in most human cancers.

188 irus (CMV) reactivation in mediating adverse clinical outcomes in nonimmunosuppressed adults with cri

189 ing disorders may be associated with adverse clinical outcomes in patients following invasive mechani

190 We compared the early clinical outcomes in patients undergoing RA using radial

191 ease (ECD) is associated with less favorable clinical outcomes in patients with acute ischemic stroke

192 the association of guideline adherence with clinical outcomes in patients with asymptomatic severe a

193 o, and its expression correlates with better clinical outcomes in patients with hepatitis C cirrhosis

194 We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Cr

195 peutic opportunity for potentially improving clinical outcomes in patients with multi-hit injuries.

196 investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes melli

197 nuate inflammation may be needed to optimize clinical outcomes in persons with HIV infection.

198 lso, its low expression correlates with poor clinical outcomes in renal cell carcinoma.

199 s, suggesting an independent contribution to clinical outcomes in resource-limited settings.

200 hat their combination could promote superior clinical outcomes in root coverage procedures.

201 the examination period, as measured with the Clinical Outcomes in Routine Evaluation Outcome Measure

202 een Zika virus infection and each of the two clinical outcomes in ten dimensions: temporality, biolog

203 itanium plates can significantly improve the clinical outcomes in the surgical removal of bone tumor.

204 y intervention or closer monitoring improves clinical outcomes in these patients.

205 n reduce disease burden and may help improve clinical outcomes in this vulnerable patient population.

206 onversion, which is associated with improved clinical outcomes, in a higher proportion of patients th

207 survivorship care plans to show benefits in clinical outcomes, in this case, showing increased physi

208 Secondary clinical outcomes included organ-specific symptoms, medi

209 Clinical outcomes included overall survival (OS), event-

210 to-severe LCI and other prespecified non-LCI clinical outcomes including all-cause pneumonia and acut

211 e effect of routine POCT on a broad range of clinical outcomes including antibiotic use.

212 atoduodenectomy was associated with a better clinical outcome, including lower mortality, compared wi

213 n by osteoclasts (OCs) can result in serious clinical outcomes, including bone loss that may weaken s

214 Incidence of adverse clinical outcomes, including need for inotropes, mechani

215 tment system and of management strategy with clinical outcomes, including stroke and death, was also

216 h colorectal cancer was associated with poor clinical outcome, irrespective of HIF-1 In addition, LOX

217 Finally, we describe clinical outcomes, limitations and future applications o

218 Improvement of clinical outcome mainly relies on the declaration of adv

219 Secondary end points included clinical outcomes (major adverse cardiac events), use of

220 ed the variance in cognitive performance and clinical outcome measures, independent of the associated

221 ing provide superior short-term or long-term clinical outcomes, more favorable patient-reported outco

222 kinase inhibitor (TKI) therapy has improved clinical outcome, most ALL patients relapse following tr

223 t relapse or severe withdrawal symptoms) and clinical outcomes (neuropsychiatric symptoms, cognitive

224 Failure to improve clinical outcome occurred even though a reduction in VWF

225 maximum follow-up period of 5 years, adverse clinical outcomes occurred in 39 patients with at least

226 This unique mouse model recapitulates a clinical outcome of a hyporesponsive HPA stress axis, an

227 s at diagnosis as a predictive biomarker for clinical outcome of breast cancer patients.

228 calcitonin, has the potential to improve the clinical outcome of children with febrile illnesses whil

229 e of this trial was to determine whether the clinical outcome of febrile children managed by the e-PO

230 oural diagnosis, brain metabolism and 1-year clinical outcome of individual patients.

231 o reduce the cerebral damage and improve the clinical outcome of ischemic stroke.

232 les, and it has heterogeneous effects on the clinical outcome of P. falciparum infection.

233 tegrating FFR on management decisions and on clinical outcome of patients with ACS undergoing coronar

234 This study sought to determine the clinical outcome of patients with concomitant moderate A

235 disparities in the diagnosis, treatment, and clinical outcome of patients with PAH has not been syste

236 el potential molecular target to improve the clinical outcome of severely burned patients.

237 To demonstrate critical techniques and clinical outcome of TIPS on liver cirrhosis-related thro

238 We aimed to examine the clinical outcomes of a bioresorbable polymer sirolimus-e

239 tudies investigating the pharmacokinetic and clinical outcomes of a new DCB to treat femoropopliteal

240 ce of positive donor rim fungal cultures and clinical outcomes of all grafts using contaminated tissu

241 ed to characterize the anesthesia choice and clinical outcomes of all US patients undergoing elective

242 inical presentation, clinical treatment, and clinical outcomes of atrial fibrillation (AF), sustained

243 d paclitaxel delivery promise to improve the clinical outcomes of first-generation PES.

244 To compare the long-term clinical outcomes of fresh versus frozen corneal graft c

245 Prevalence and clinical outcomes of MGUS in kidney transplant (KT) reci

246 he TMVR multicenter registry, procedural and clinical outcomes of mitral ViV and ViR were compared ac

247 High-flow nasal cannula (HFNC) improves the clinical outcomes of nonintubated patients with acute hy

248 We therefore studied the severity and clinical outcomes of nonobese NAFLD patients.

249 d MEKi) therapies have markedly improved the clinical outcomes of patients with metastatic melanoma.

250 The clinical outcomes of patients with PACs have significant

251 apeutic strategy to minimize the detrimental clinical outcomes of prolonged cold IRI during RTx.

252 s of key pathways associated with downstream clinical outcomes of sepsis and whether there were diffe

253 To compare clinical outcomes of transepithelial corneal cross-linki

254 te the prevalence, spatial distribution, and clinical outcomes of undertriage of firearm-related inju

255 Clinical outcomes of using PRK with application of MMC f

256 features of donor tissue that may influence clinical outcome or complication rate after deep anterio

257 correlation, linear regression analysis for clinical outcome parameter and logistic regression analy

258 As expected, no effects were seen on clinical outcome parameters in this short-term trial.

259 Clinical outcome parameters included best spectacle corr

260 f anterior corneal stroma were correlated to clinical outcome parameters of recipient eyes 12 months

261 isk factors for alcohol withdrawal syndrome, clinical outcomes, pharmacologic treatment for alcohol w

262 Our data suggest that the wide spectrum of clinical outcomes, ranging from mental retardation to mi

263 ions have been linked to different levels of clinical outcomes, ranging from mild rash and fever to s

264 onic hepatitis B (CHB) exhibits a variety of clinical outcomes, ranging from spontaneous resolution o

265 xtent of its antigen diversity and impact on clinical outcomes remain poorly understood.

266 nutrition as a combined modality therapy on clinical outcomes remains controversial.

267 relationship between iAEs and postoperative clinical outcomes remains largely unknown.

268 (AT) gene expression, yet the relation with clinical outcomes remains unclear.We evaluated AT transc

269 addition, correlate antioxidant levels with clinical outcome scores to determine a possible predicti

270 However, overall clinical outcome showed no significant difference betwee

271 ation (n=58), the primary and most secondary clinical outcomes significantly favoured MT (absolute di

272 mber of fusions, the age of patients and the clinical outcome, strongly suggesting that genomic insta

273 ntify patients who share disease biology and clinical outcome, such that therapies, both existing and

274 e multicentre-validated AVICH score predicts clinical outcome superior to pre-existing scores.

275 ive repeated culture was predictive of worse clinical outcome than those who achieved microbiological

276 herapy (CBT) would be associated with better clinical outcomes than solution-focused brief therapy an

277 better BP control or for preventing adverse clinical outcomes that are related to elevated BP?

278 w of FGF23 biology and physiology, summarize clinical outcomes that have been associated with FGF23,

279 trating the beneficial effects of statins on clinical outcomes, the mechanisms underlying these effec

280 th brain atrophy (p.Ser94Arg) and extend the clinical outcomes to a more severe spectrum with infanti

281 g single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in

282 te end points such as infarct size to larger clinical outcome trials.

283 ive of this study was to investigate whether clinical outcomes vary by protein or energy intake in pa

284 rlying this sexually dimorphic difference in clinical outcome, we leveraged Nf1 optic glioma (Nf1-OPG

285 Clinical outcomes were also assessed.

286 tionally, associations between DARC SNPs and clinical outcomes were analysed in a cohort of poorly co

287 AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 crit

288 Clinical outcomes were better in the direct group, with

289 Hazard ratios (HRs) for clinical outcomes were calculated for children with asth

290 Clinical outcomes were compared between patients display

291 Clinical outcomes were compared using point estimates fo

292 , 4, 5, and 10 years, and relationships with clinical outcomes were examined.

293 sociations of CEE alone or CEE+MPA with most clinical outcomes were highly concordant between NHS and

294 resh and frozen corneal donors offer similar clinical outcomes when used as carriers for the B-KPro,

295 37.0-38.8) was the most sensitive for major clinical outcomes, whereas using the ADA HbA1c cutoff (2

296 k ratios (aRRR) for associations of parental clinical outcome with offspring allergic disease were es

297 om randomized trials is critical to evaluate clinical outcomes with BVS on complete resolution of the

298 mutations in glioma is prognostic for better clinical outcomes with longer patient survival.

299 ents also are available, but the evidence on clinical outcomes with these approaches is limited.

300 However, long-term clinical outcomes with this regimen and predictive infor